Ambea AB's revenue for the
three
months ended in Mar. 2026 was kr4,220 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was kr16,615 Mil.
Ambea AB's Revenue per Share for the
three
months ended in Mar. 2026 was kr51.65.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr199.16.
Good Sign:
Ambea AB has shown predictable revenue and earnings growth.
During the past 12 months, the average Revenue per Share Growth Rate of Ambea AB was 17.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 12.50% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 10.40% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 11.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 12 years, Ambea AB's highest 3-Year average Revenue per Share Growth Rate was 20.10% per year. The lowest was 1.40% per year. And the median was 12.20% per year.
Ambea AB (CHIX:AMBEAs) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Ambea AB Revenue Related Terms
Ambea AB Revenue Historical Data
* Premium members only.
The historical data trend for Ambea AB's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Ambea AB's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ambea AB Revenue vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Ambea AB's Revenue distribution charts can be found below:
* The bar in red indicates where Ambea AB's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr16,615 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ambea AB (CHIX:AMBEAS) has a Revenue of kr16,615 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Ambea AB and its competitors.
Is Ambea AB's Revenue too high?
Ambea AB's current Revenue is kr16,615 Mil. Overall, Ambea AB has a GF Score™ of 83/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ambea AB's Revenue compare to HCA and THC?
Ambea AB's Revenue of kr16,615 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Healthcare Providers & Services company?
A good Revenue depends on the Healthcare Providers & Services industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Ambea AB and its competitors. Ambea AB's current Revenue is kr16,615 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ambea AB stock overvalued right now?
Based on GuruFocus' analysis, Ambea AB (CHIX:AMBEAS) is currently considered Significantly Overvalued. The stock's GF Value™ is kr110.46, compared to a current price of kr144.20 — trading 30.5% above its estimated fair value. The current Revenue is kr16,615 Mil. Ambea AB's overall GF Score™ is 83/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Ambea AB (CHIX:AMBEAS), the current Revenue is kr16,615 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ambea AB (CHIX:AMBEAS) Overvalued in 2026?
Based on GuruFocus' analysis, Ambea AB stock appears to be overvalued.
The current stock price of kr144.20 is trading 30.5% above its estimated GF Value™ of kr110.46.
GuruFocus considers Ambea AB to be Significantly Overvalued.
Key valuation signals for CHIX:AMBEAS:
Revenue: kr16,615 Mil
GF Value™: kr110.46 vs. price of kr144.20 (30.5% above fair value)
No single metric tells the full story. See the CHIX:AMBEAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ambea AB is a Swedish care-provider group focused on elderly care, disability care, psychosocial support, housing, staffing, and training across the Nordic region. The company's segment includes: i) Nytida: Comprises social care services for children, youth and adults, in Sweden, ii) Vardaga: Comprises nursing homes and home care in Sweden, iii) Stendi: Comprises social care for children, youth and adult in Norway, iv) Validia: Comprises social care for children, v) Altiden: Comprises social care for children, youth and adults as well as elderly care in Denmark, and vi) Klara: Comprises competence and staffing solutions for elderly and social care, and student health services in Sweden. The majority of the company's revenue is derived from the Vardaga segment.
83GF Score
Get the complete analysis for CHIX:AMBEAS
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:AMBEAS has been successfully added to your 
